Table 3 Effects of antiplatelet drugs on the results of fecal immunochemical test in colorectal neoplasms screening.
Measure | Outcome | Anti-platelet agents | p-value | |
|---|---|---|---|---|
Yes (n = 129) | No (n = 614) | |||
Sensitivity | CN | 31/53 (58.5%) CI (44.1–71.9%) | 122/217 (56.0%) CI (49.3–62.9%) | 0.7650 |
CRC | 8/10 (80.0%) CI (37.7–56.5%) | 35/43 (81.4%) CI (66.6–91.6%) | 0.9191 | |
CRC + AA | 17/24 (70.8%) CI (48.9–87.4%) | 75/99 (75.8%) CI (66.1–83.8%) | 0.6182 | |
NAA only | 14/30 (46.7%) CI (28.3–65.7%) | 47/118 (39.8%) CI (30.9–49.3%) | 0.4970 | |
Specificity | CN | 47/76 (61.8%) CI (50.0–72.8%) | 223/397 (56.2%) CI (51.1–61.1%) | 0.3602 |
CRC | 67/119 (56.3%) CI (46.9–65.4%) | 310/571 (54.3%) CI (50.1–58.4%) | 0.6884 | |
CRC + AA | 62/105 (59.0%) CI (52.7–61.4%) | 294/515 (57.1%) CI (52.7–61.4%) | 0.6563 | |
NAA only | 47/76 (61.8%) CI (50.0–72.8%) | 223/397 (56.2%) CI (51.1–61.1%) | 0.3602 | |
PPV | CN | 31/60 (51.7%) CI (38.4–64.8%) | 122/296 (41.2%) CI (35.6–47.1%) | 0.1360 |
CRC | 8/60 (13.3%) CI (5.9–24.6%) | 35/296 (11.8%) CI (8.4–16.1%) | 0.7436 | |
CRC + AA | 17/60 (28.3%) CI (17.5–41.4%) | 75/296 (25.3%) CI (20.5–30.7%) | 0.6289 | |
NAA only | 14/43 (32.6%) CI (19.1–48.5%) | 47/221 (21.3%) CI (16.1–27.3%) | 0.1080 | |
NPV | CN | 47/69 (68.1%) CI (55.8–78.8%) | 223/318 (70.1%) CI (64.8–75.1%) | 0.7418 |
CRC | 67/69 (97.1%) CI (89.9–99.6%) | 310/318 (97.5%) CI (95.1–98.9%) | 0.8558 | |
CRC + AA | 62/69 (89.9%) CI (80.2–95.8%) | 294/318 (92.5%) CI (89.0–95.1%) | 0.4712 | |
NAA only | 47/63 (74.6%) CI (62.1–84.7%) | 223/294 (75.9%) CI (70.5–80.6%) | 0.8343 | |
